Rana R McKay1, Dominick Bossé1, Toni K Choueiri1. 1. Rana R. McKay, Moores Cancer Center, University of California San Diego, San Diego, CA; Dominick Bossé and Toni K. Choueiri, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Dominick Bossé, The Ottawa Hospital Cancer Center, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Abstract
PURPOSE: To outline current practices and challenges in the systemic management of patients with advanced renal cell carcinoma (RCC). DESIGN: We conducted a focused review of hallmark randomized controlled trials informing the systemic treatment of patients with RCC. We concentrated on trials informing the use of combination therapies, therapy in both treatment-naïve and previously treated patients, sequential treatment strategies, and schedules. RESULTS: The systemic treatment of advanced RCC has experienced tremendous progress over the past 15 years. An improved understanding of the canonical pathways implicated in RCC pathogenesis has resulted in the development of molecularly targeted and immunotherapy options for patients. These therapies have replaced cytokine-based treatments as the standard of care for patients with advanced RCC. Until recently, sequential vascular endothelial growth factor (VEGF)-targeted therapy or VEGF-targeted therapy followed by mammalian target of rapamycin inhibition has been the prevailing treatment paradigm for patients. However, newer agents such as cabozantinib and nivolumab have challenged this traditional approach. In addition, combination treatments including nivolumab plus ipilimumab and atezolizumab plus bevacizumab have transformed the RCC treatment landscape, and other doublet combinations in clinical testing will likely continue to alter the treatment paradigm in RCC. Currently, factors that inform treatment selection between different therapy options include performance status, comorbidities, prognostic risk stratification, treatment adverse event profile, and mode of administration, with no Level I evidence for predictive biomarker use in clinic. CONCLUSIONS: The treatment options for advanced RCC are rapidly evolving since the introduction of VEGF-targeted therapy, immunotherapy with checkpoint blockade and, more recently, combination regimens. Despite the success of these regimens, advanced RCC remains a largely incurable disease, and additional strategies are warranted.
PURPOSE: To outline current practices and challenges in the systemic management of patients with advanced renal cell carcinoma (RCC). DESIGN: We conducted a focused review of hallmark randomized controlled trials informing the systemic treatment of patients with RCC. We concentrated on trials informing the use of combination therapies, therapy in both treatment-naïve and previously treated patients, sequential treatment strategies, and schedules. RESULTS: The systemic treatment of advanced RCC has experienced tremendous progress over the past 15 years. An improved understanding of the canonical pathways implicated in RCC pathogenesis has resulted in the development of molecularly targeted and immunotherapy options for patients. These therapies have replaced cytokine-based treatments as the standard of care for patients with advanced RCC. Until recently, sequential vascular endothelial growth factor (VEGF)-targeted therapy or VEGF-targeted therapy followed by mammalian target of rapamycin inhibition has been the prevailing treatment paradigm for patients. However, newer agents such as cabozantinib and nivolumab have challenged this traditional approach. In addition, combination treatments including nivolumab plus ipilimumab and atezolizumab plus bevacizumab have transformed the RCC treatment landscape, and other doublet combinations in clinical testing will likely continue to alter the treatment paradigm in RCC. Currently, factors that inform treatment selection between different therapy options include performance status, comorbidities, prognostic risk stratification, treatment adverse event profile, and mode of administration, with no Level I evidence for predictive biomarker use in clinic. CONCLUSIONS: The treatment options for advanced RCC are rapidly evolving since the introduction of VEGF-targeted therapy, immunotherapy with checkpoint blockade and, more recently, combination regimens. Despite the success of these regimens, advanced RCC remains a largely incurable disease, and additional strategies are warranted.
Authors: Daniel J George; Colin Hessel; Susan Halabi; M Dror Michaelson; Olwen Hahn; Meghara Walsh; Joel Picus; Eric J Small; Shaker Dakhil; Darren R Feldman; Milan Mangeshkar; Christian Scheffold; Michael J Morris; Toni K Choueiri Journal: Oncologist Date: 2019-08-09
Authors: Josefine Redig; Johan Dalén; Ulrika Harmenberg; Magnus Lindskog; Börje Ljungberg; Sven Lundstam; Rickard Sandin; Thomas Wahlgren; Örjan Åkerborg; Maria Jakobsson Journal: Cancer Manag Res Date: 2019-02-08 Impact factor: 3.989
Authors: David D Stenehjem; Andrew W Hahn; David M Gill; Daniel Albertson; Banumathy Gowrishankar; Joseph Merriman; Archana M Agarwal; Venkata Thodima; Erik B Harrington; Trang H Au; Benjamin L Maughan; Jane Houldsworth; Sumanta K Pal; Neeraj Agarwal Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240
Authors: Alice C Fan; Vandana Sundaram; Aya Kino; Heiko Schmiedeskamp; Thomas J Metzner; Aya Kamaya Journal: Cancers (Basel) Date: 2019-04-30 Impact factor: 6.639